Clinical trial • Phase II • Respiratory

AZD0292 for Bronchiectasis with chronic Pseudomonas aeruginosa colonization

Phase II trial of AZD0292 for Bronchiectasis with chronic Pseudomonas aeruginosa colonization.

Overview

Trial Therapeutic Area
Respiratory
Trial Disease
Bronchiectasis with chronic Pseudomonas aeruginosa colonization
Trial Stage
Phase II
Drug Modality
Monoclonal antibody
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
15-07-2025
First CTIS Authorization Date
31-10-2025

Trial design

Randomised, placebo for azd0292 (matching placebo); no dose or schedule specified in the provided ctis metadata-controlled Phase II trial across 50 sites in Italy, Belgium, Greece and others.

Randomised
Yes
Comparator
Placebo for AZD0292 (matching placebo); no dose or schedule specified in the provided CTIS metadata
Target Sample Size
323

Eligibility

Recruits 323 paediatric patients.

Pregnancy Exclusion
Female participants who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration
Vulnerable Population
Vulnerable population flag selected in trial metadata. Eligibility requires participants to be capable of giving signed informed consent. Subject information and informed consent forms (ICFs) are provided (adult and pregnancy-specific ICFs, multiple language versions listed). No specific assent procedures for minors or alternative consent-by-proxy wording are provided in the available materials.

Inclusion criteria

  • {"criterion_text":"- Participant must be ≥ 18 years of age at the time of signing the informed consent"}
  • {"criterion_text":"- Weight ≥ 35 kg"}
  • {"criterion_text":"- Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility."}
  • {"criterion_text":"- Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics"}
  • {"criterion_text":"- Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization"}
  • {"criterion_text":"- Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value at screening."}
  • {"criterion_text":"- Presence of positive (PCR or culture) PsA in an airway sample at least once in the last 24 months prior to screening"}
  • {"criterion_text":"- Presence of culture positive PsA in sputum at least within 5 weeks of randomization a) Participants who have previously received PsA eradication therapy, as determined appropriate by their treating provider, but remain colonized with PsA are eligible for the study."}
  • {"criterion_text":"- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol"}

Exclusion criteria

  • {"criterion_text":"- Primary lung diagnosis other than bronchiectasis"}
  • {"criterion_text":"- Receipt of investigational products indicated for the treatment or prevention of bronchiectasis exacerbations or expected receipt during the study"}
  • {"criterion_text":"- Participants with CF on CFTR modulator therapies which are newly initiated within the previous 3 months prior to screening"}
  • {"criterion_text":"- Female participants who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration"}
  • {"criterion_text":"- Evidence of active tuberculosis or active nontuberculous mycobacteria being treated or requiring treatment. Active tuberculosis may be suspected if a participant has a cough for more than 2 weeks with concurrent fever, night sweats, weight loss, or hemoptysis. Investigation for active or latent TB, with interferon gamma release assay (IGRA) and/or chest X-ray, should be considered if deemed clinically indicated by the Investigator. Participants currently receiving treatment for active TB or nontuberculous mycobacteria may be considered after completion of an appropriate course of therapy"}
  • {"criterion_text":"- Evidence of an active allergic bronchopulmonary aspergillosis being treated or requiring treatment"}
  • {"criterion_text":"- Need for long term supplemental oxygen. Oxygen use for ambulation and relief of breathlessness after exercise is allowed"}
  • {"criterion_text":"- Malignancy, current or within the previous 5 years, except for stable prostate cancer, adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than one year prior to enrolment"}
  • {"criterion_text":"- AIDS or Advanced human immunodeficiency virus disease (CD4 count of < 200 cells/mm3)"}
  • {"criterion_text":"- History of severe adverse reaction associated with a mAb, and/or history of severe allergic reaction (eg, anaphylaxis that required the use of epinephrine/adrenaline or hospitalization), and/or history of immune complex disease (Type III hypersensitivity reactions) to monoclonal antibody administration"}
  • {"criterion_text":"- Treatment with long term anti-PsA antibiotics, macrolides, or DPP-1 inhibitors, which are newly initiated within the 3 months prior to screening"}
  • {"criterion_text":"- Chronic immunosuppressive therapy (including prednisolone > 5 mg or equivalent) newly initiated within the last 3 months"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Annualized rate of exacerbations over a variable follow-up time","definition_or_measurement_approach":"Annualized rate of exacerbations calculated over a variable follow-up period (as stated: 'Annualized rate of exacerbations over a variable follow-up time')"}

Secondary endpoints

  • {"endpoint_text":"- Annualized rate of severe exacerbations over a variable follow-up time","definition_or_measurement_approach":"Annualized rate of severe exacerbations over a variable follow-up period"}
  • {"endpoint_text":"- Change from baseline in QoL-B-RSS","definition_or_measurement_approach":"Change from baseline measured by the QoL-B Respiratory Symptom Scale Score (QoL-B-RSS)"}
  • {"endpoint_text":"- Change from baseline in SGRQ score","definition_or_measurement_approach":"Change from baseline measured by the St George's Respiratory Questionnaire (SGRQ) score"}
  • {"endpoint_text":"- Time to first moderate or severe exacerbation and Time to first severe exacerbation","definition_or_measurement_approach":"Time-to-event analyses for time to first moderate or severe exacerbation and time to first severe exacerbation"}
  • {"endpoint_text":"- Serum PK concentrations of AZD0292 at all collected timepoints","definition_or_measurement_approach":"Serum pharmacokinetic concentrations measured at all collected timepoints"}
  • {"endpoint_text":"- Incidence of ADA to AZD0292 and ADA titers of AZD0292 at all collected timepoints","definition_or_measurement_approach":"Incidence and titers of anti-drug antibodies (ADA) measured at all collected timepoints"}
  • {"endpoint_text":"- Occurrence of AEs collected from the first dose through 12 weeks after last IMP administration and SAEs, AESIs, and MAAEs, collected throughout the study","definition_or_measurement_approach":"Safety events collected from first dose through 12 weeks after last IMP for AEs and throughout study for SAEs, adverse events of special interest (AESIs), and medically attended adverse events (MAAEs)"}

Recruitment

Planned Sample Size
323
Recruitment Window Months
31
Consent Approach
Participants must provide signed informed consent ('Capable of giving signed informed consent' is an inclusion criterion). Multiple ICF documents are provided including main ICFs and pregnancy-specific ICFs; language-specific ICFs are available (English, French, Dutch, Greek and others as listed). No details on assent for minors are provided in the available documents.

Methods

  • K1_Recruitment arrangements documents (country-specific recruitment arrangements provided)
  • K2 recruitment materials: Letter to participant (document 'K2_Recruitment material_Letter to participant')
  • K2 recruitment materials: Poster for advertisement (document 'K2_Recruitment material_Poster for advertisement')

Geography

Total Number Of Sites
50
Total Number Of Participants
112

Italy

Earliest CTIS Part Ii Submission Date
20-10-2025
Latest Decision Or Authorization Date
04-11-2025
Processing Time Days
15
Number Of Sites
8
Number Of Participants
15

Sites

Site Name
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Department Name
UOC di Pneumologia
Principal Investigator Name
Salvatore Battaglia
Principal Investigator Email
salvatore.battaglia@unipa.it
Contact Person Name
Salvatore Battaglia
Contact Person Email
salvatore.battaglia@unipa.it
Site Name
Azienda Ospedaliera Di Perugia
Department Name
S.C. Pneumologia
Principal Investigator Name
Roberto Lipsi
Principal Investigator Email
roberto.lipsi@ospedale.perugia.it
Contact Person Name
Roberto Lipsi
Site Name
Humanitas Mirasole S.p.A.
Department Name
UO. Pneumologia 1
Principal Investigator Name
Edoardo Simonetta
Principal Investigator Email
edoardo.simonetta@humanitas.it
Contact Person Name
Edoardo Simonetta
Contact Person Email
edoardo.simonetta@humanitas.it
Site Name
Irccs San Raffaele Roma S.r.l.
Department Name
Cardiopulmonary Rehabilitation
Principal Investigator Name
Franco Pasqua
Principal Investigator Email
franco.pasqua@sanraffaele.it
Contact Person Name
Franco Pasqua
Contact Person Email
franco.pasqua@sanraffaele.it
Site Name
Fondazione IRCCS Policlinico San Matteo
Department Name
S.C. Pneumologia
Principal Investigator Name
Angelo Guido Corsico
Principal Investigator Email
corsico@unipv.it
Contact Person Name
Angelo Guido Corsico
Contact Person Email
corsico@unipv.it
Site Name
Azienda Ospedaliero Universitaria Delle Marche
Department Name
Respiratory Medicine Unit
Principal Investigator Name
Martina Bonifazi
Principal Investigator Email
martina.bonifazi@ospedaliriuniti.marche.it
Contact Person Name
Martina Bonifazi
Site Name
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Department Name
SC Pneumologia e Fibrosi Cistica
Principal Investigator Name
Francesco Bruno Arturo Blasi
Principal Investigator Email
francesco.blasi@policlinico.mi.it
Contact Person Name
Francesco Bruno Arturo Blasi
Site Name
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone (duplicate entry consolidation if present)
Department Name
UOC di Pneumologia

Belgium

Earliest CTIS Part Ii Submission Date
20-10-2025
Latest Decision Or Authorization Date
03-11-2025
Processing Time Days
14
Number Of Sites
4
Number Of Participants
7

Sites

Site Name
Universitair Ziekenhuis Gent
Department Name
Respiratory Medicine
Principal Investigator Name
Eva Van Braeckel
Principal Investigator Email
eva.vanbraeckel@ugent.be
Contact Person Name
Eva Van Braeckel
Contact Person Email
eva.vanbraeckel@ugent.be
Site Name
Vitaz
Department Name
Pulmonary and Infectious Diseases
Principal Investigator Name
Pieter Goeminne
Principal Investigator Email
pieter.goeminne@vitaz.be
Contact Person Name
Pieter Goeminne
Contact Person Email
pieter.goeminne@vitaz.be
Site Name
UZ Leuven
Department Name
Pulmonology
Principal Investigator Name
Natalie Lorent
Principal Investigator Email
natalie.lorent@uzleuven.be
Contact Person Name
Natalie Lorent
Contact Person Email
natalie.lorent@uzleuven.be
Site Name
Centre hospitalier universitaire de Liege
Department Name
Pneumologie - Allergologie
Principal Investigator Name
Doriane Calmés
Principal Investigator Email
dcalmes@chuliege.be
Contact Person Name
Doriane Calmés
Contact Person Email
dcalmes@chuliege.be

Greece

Earliest CTIS Part Ii Submission Date
21-10-2025
Latest Decision Or Authorization Date
13-11-2025
Processing Time Days
23
Number Of Sites
8
Number Of Participants
20

Sites

Site Name
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara
Department Name
2nd Department of Respiratory Medicine
Principal Investigator Name
Stylianos Loukidis
Principal Investigator Email
loukstel@med.uoa.gr
Contact Person Name
Stylianos Loukidis
Contact Person Email
loukstel@med.uoa.gr
Site Name
General University Hospital Of Patras
Department Name
Department of Respiratory Medicine
Principal Investigator Name
Argyrios Tzouvelekis
Principal Investigator Email
argyris.tzouvelekis@gmail.com
Contact Person Name
Argyrios Tzouvelekis
Contact Person Email
argyris.tzouvelekis@gmail.com
Site Name
University General Hospital Of Ioannina
Department Name
Respiratory Clinic
Principal Investigator Name
Konstantinos Kostikas
Principal Investigator Email
ktkostikas@gmail.com
Contact Person Name
Konstantinos Kostikas
Contact Person Email
ktkostikas@gmail.com
Site Name
General University Hospital Of Larissa
Department Name
Pulmonary Clinic
Principal Investigator Name
Zoe Daniil
Principal Investigator Email
zdaniil@med.uth.gr
Contact Person Name
Zoe Daniil
Contact Person Email
zdaniil@med.uth.gr
Site Name
Geniko Nosokomeio Thessalonikis George Papanikolaou
Department Name
Respiratory Department
Principal Investigator Name
Konstantinos Porpodis
Principal Investigator Email
kporpodis@yahoo.gr
Contact Person Name
Konstantinos Porpodis
Contact Person Email
kporpodis@yahoo.gr
Site Name
Sismanogleio General Hospital
Department Name
Adult CF Unit
Principal Investigator Name
Filia Diamantea
Principal Investigator Email
Fdiamantea@gmail.com
Contact Person Name
Filia Diamantea
Contact Person Email
Fdiamantea@gmail.com
Site Name
Thoracic General Hospital Of Athens I Sotiria
Department Name
1st University Department of Respiratory Medicine
Principal Investigator Name
Petros Bakakos
Principal Investigator Email
petros44@hotmail.com
Contact Person Name
Petros Bakakos
Contact Person Email
petros44@hotmail.com
Site Name
Athens Medical Center S.A.
Department Name
Respiratory Department
Principal Investigator Name
Dimosthenis Papapetrou
Principal Investigator Email
dimospapapetroudsa@hotmail.com
Contact Person Name
Dimosthenis Papapetrou
Contact Person Email
dimospapapetroudsa@hotmail.com

Germany

Earliest CTIS Part Ii Submission Date
15-10-2025
Latest Decision Or Authorization Date
03-11-2025
Processing Time Days
19
Number Of Sites
7
Number Of Participants
17

Sites

Site Name
IKF Pneumologie GmbH & Co. KG
Principal Investigator Name
Andreas Eich
Principal Investigator Email
eich@ikf-pneumologie.de
Contact Person Name
Andreas Eich
Contact Person Email
eich@ikf-pneumologie.de
Site Name
Klinikum Konstanz GmbH
Department Name
Studienzentrums der Inneren Medizin
Principal Investigator Name
Stephan Walrerspacher
Principal Investigator Email
stephan.walterspacher@glkn.de
Contact Person Name
Stephan Walrerspacher
Contact Person Email
stephan.walterspacher@glkn.de
Site Name
Lungenheilkunde München-Pasing
Principal Investigator Name
Rainald Fischer
Principal Investigator Email
rainald.fischer@gmail.com
Contact Person Name
Rainald Fischer
Contact Person Email
rainald.fischer@gmail.com
Site Name
Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbH
Department Name
Klinik für Pneumologie
Principal Investigator Name
Sivagurunathan Sutharsan
Principal Investigator Email
sivagurunathan.sutharsan@rlk.uk-essen.de
Contact Person Name
Sivagurunathan Sutharsan
Site Name
LMU Klinikum Muenchen AöR
Department Name
Medizinische Klinik und Poliklinik V
Principal Investigator Name
Pontus Mertsch
Principal Investigator Email
Pontus.Mertsch@med.uni-muenchen.de
Contact Person Name
Pontus Mertsch
Site Name
Medizinische Hochschule Hannover
Department Name
Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie
Principal Investigator Name
Felix Ringshausen
Principal Investigator Email
Ringshausen.Felix@mh-hannover.de
Contact Person Name
Felix Ringshausen
Site Name
Pneumologicum Halle
Principal Investigator Name
Peter-Uwe Haase
Principal Investigator Email
mail@pneumologicum-halle.de
Contact Person Name
Peter-Uwe Haase
Contact Person Email
mail@pneumologicum-halle.de

Spain

Earliest CTIS Part Ii Submission Date
20-10-2025
Latest Decision Or Authorization Date
04-11-2025
Processing Time Days
15
Number Of Sites
8
Number Of Participants
15

Sites

Site Name
Hospital De Merida
Department Name
Neumology
Principal Investigator Name
Antonio Manuel Perez Fernandez
Principal Investigator Email
ampf7395@gmail.com
Contact Person Name
Antonio Manuel Perez Fernandez
Contact Person Email
ampf7395@gmail.com
Site Name
Hospital Clinic De Barcelona
Department Name
Neumology
Principal Investigator Name
Oriol Sibila Vidal
Principal Investigator Email
osibila@clinic.cat
Contact Person Name
Oriol Sibila Vidal
Contact Person Email
osibila@clinic.cat
Site Name
Hospital Del Mar
Department Name
Neumology
Principal Investigator Name
Esther Barreiro Portela
Principal Investigator Email
ebarreiro@researchmar.net
Contact Person Name
Esther Barreiro Portela
Contact Person Email
ebarreiro@researchmar.net
Site Name
Hospital Universitario Fundacion Jimenez Diaz
Department Name
Neumology
Principal Investigator Name
Carolina Gotera Rivera
Principal Investigator Email
carolina.gotera@fjd.es
Contact Person Name
Carolina Gotera Rivera
Contact Person Email
carolina.gotera@fjd.es
Site Name
Hospital Vithas Xanit Internacional
Department Name
Neumology
Principal Investigator Name
Gustavo de Luiz Martinez
Principal Investigator Email
gdeluizmartinez@yahoo.es
Contact Person Name
Gustavo de Luiz Martinez
Contact Person Email
gdeluizmartinez@yahoo.es
Site Name
Hospital Universitario Y Politecnico La Fe
Department Name
Neumology
Principal Investigator Name
Raul Mendez Ocana
Principal Investigator Email
mendez_rau@gva.es
Contact Person Name
Raul Mendez Ocana
Contact Person Email
mendez_rau@gva.es
Site Name
Hospital Universitario La Paz
Department Name
Neumology
Principal Investigator Name
Ester Zamarron de Lucas
Principal Investigator Email
esterzamarron@gmail.com
Contact Person Name
Ester Zamarron de Lucas
Contact Person Email
esterzamarron@gmail.com
Site Name
Hospital Universitario Dr Peset Aleixandre
Department Name
Neumology
Principal Investigator Name
Ruben Lera Alvarez
Principal Investigator Email
ruben_lera@hotmail.com
Contact Person Name
Ruben Lera Alvarez
Contact Person Email
ruben_lera@hotmail.com

Denmark

Earliest CTIS Part Ii Submission Date
20-10-2025
Latest Decision Or Authorization Date
03-11-2025
Processing Time Days
14
Number Of Sites
4
Number Of Participants
18

Sites

Site Name
Region Sjaelland
Department Name
Dept of Internal medicine
Principal Investigator Name
Christian Meyer
Principal Investigator Email
cnm@regionsjaelland.dk
Contact Person Name
Christian Meyer
Contact Person Email
cnm@regionsjaelland.dk
Site Name
Region Hovedstaden
Department Name
Respiratory Medicine
Principal Investigator Name
Charlotte Suppli Ulrik
Principal Investigator Email
charlotte.suppli.ulrik@regionh.dk
Contact Person Name
Charlotte Suppli Ulrik
Site Name
Aalborg University Hospital
Department Name
Department of Respiratory Diseases
Principal Investigator Name
Ulla Møller Weinreich
Principal Investigator Email
ulw@rn.dk
Contact Person Name
Ulla Møller Weinreich
Contact Person Email
ulw@rn.dk
Site Name
Odense University Hospital
Department Name
Department of Respiratory Medicine
Principal Investigator Name
Sofie Lock Johansson
Principal Investigator Email
Sofie.johansson@rsyd.dk
Contact Person Name
Sofie Lock Johansson
Contact Person Email
Sofie.johansson@rsyd.dk

France

Earliest CTIS Part Ii Submission Date
16-10-2025
Latest Decision Or Authorization Date
14-11-2025
Processing Time Days
29
Number Of Sites
8
Number Of Participants
14

Sites

Site Name
Centre Hospitalier Regional De Marseille
Department Name
Pôle Thorax, département de Pneumologie, Allergologie et Cancérologie Unité de Pneumologie aigüe
Principal Investigator Name
Marion Gouitaa
Principal Investigator Email
marion.gouitaa@ap-hm.fr
Contact Person Name
Marion Gouitaa
Contact Person Email
marion.gouitaa@ap-hm.fr
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Pneumologie
Principal Investigator Name
Julie Macey
Principal Investigator Email
julie.macey@chu-bordeaux.fr
Contact Person Name
Julie Macey
Contact Person Email
julie.macey@chu-bordeaux.fr
Site Name
Centre Hospitalier Universitaire De Toulouse
Department Name
Pneumologie
Principal Investigator Name
Marlene Murris-Espin
Principal Investigator Email
murris.m@chu-toulouse.fr
Contact Person Name
Marlene Murris-Espin
Contact Person Email
murris.m@chu-toulouse.fr
Site Name
Centre Hospitalier Universitaire De Montpellier
Department Name
Service des maladies respiratoires – Departement de pneumologie
Principal Investigator Name
Arnaud Bourdin
Principal Investigator Email
a-bourdin@chu-montpellier.fr
Contact Person Name
Arnaud Bourdin
Contact Person Email
a-bourdin@chu-montpellier.fr
Site Name
Centre Hospitalier Intercommunal Creteil
Department Name
Pneumologie / UFR Sante Medecine
Principal Investigator Name
Bernard Maitre
Principal Investigator Email
bernard.maitre@chicreteil.fr
Contact Person Name
Bernard Maitre
Contact Person Email
bernard.maitre@chicreteil.fr
Site Name
Les Hopitaux Universitaires De Strasbourg
Department Name
Pneumologie
Principal Investigator Name
Loic Kassegne
Principal Investigator Email
loic.kassegne@chru-strasbourg.fr
Contact Person Name
Loic Kassegne
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Pierre-Regis Burgel
Principal Investigator Email
pierre-regis.burgel@aphp.fr
Contact Person Name
Pierre-Regis Burgel
Contact Person Email
pierre-regis.burgel@aphp.fr
Site Name
Centre Hospitalier Regional Et Universitaire De Brest
Department Name
Pneumologie
Principal Investigator Name
Raphael Le Mao
Principal Investigator Email
raphael.lemao@chu-brest.fr
Contact Person Name
Raphael Le Mao
Contact Person Email
raphael.lemao@chu-brest.fr

Netherlands

Earliest CTIS Part Ii Submission Date
27-10-2025
Latest Decision Or Authorization Date
05-11-2025
Processing Time Days
9
Number Of Sites
3
Number Of Participants
6

Sites

Site Name
Gelre Hospitals
Department Name
Pulmonary Research Department
Principal Investigator Name
Martijn Goosens
Principal Investigator Email
goosens.research@gelre.nl
Contact Person Name
Martijn Goosens
Contact Person Email
goosens.research@gelre.nl
Site Name
Amsterdam UMC Stichting
Department Name
Pulmonary Department
Principal Investigator Name
Josje Altenburg
Principal Investigator Email
j.altenburg@amsterdamumc.nl
Contact Person Name
Josje Altenburg
Contact Person Email
j.altenburg@amsterdamumc.nl
Site Name
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department Name
Pulmonary Department
Principal Investigator Name
Menno van der Eerden
Principal Investigator Email
m.vandereerden@erasmusmc.nl
Contact Person Name
Menno van der Eerden
Contact Person Email
m.vandereerden@erasmusmc.nl

Sponsor

Primary sponsor

Full Name
AstraZeneca AB
Organisation Type
Pharmaceutical company
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
AZD0292
Active Substance
AZD0292
Modality
Monoclonal antibody
Routes Of Administration
SOLUTION FOR INFUSION
Route
SOLUTION FOR INFUSION
Investigational Product Name
Placebo for AZD0292

Related trials

Other published trials that may interest you.